Alexander J. Denner - 15 Jun 2026 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Reporting relationship: Director
Issuer ticker: IRWD
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 16:42:25 UTC
Prior SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Alexander Denner

Key filing fact

Alexander J. Denner filed Form 4 for IRONWOOD PHARMACEUTICALS INC (IRWD) on 17 Jun 2026.

Key facts

This page summarizes Alexander J. Denner's Form 4 filing for IRONWOOD PHARMACEUTICALS INC (IRWD).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 17 Jun 2026, 16:42.

Change

Previous filing in this sequence was filed on 17 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001361754 Primary reporting owner

DENNER ALEXANDER J

Relationship: Director
Address: C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON
Signature: /s/ Alexander Denner
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRWD transaction

Class A Common Stock

Award

Transaction value
Shares: +4,065
Change %: +1.6%
Price: $0.000000^*
Shares after: 260,374
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1

IRWD transaction

Class A Common Stock

Award

Transaction value
Shares: +63,481
Change %: +24%
Price: $0.000000^*
Shares after: 323,855
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.

Footnote F2

The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.